Peptide particle formulation
A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which may be a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.
1. A composition, comprising:
a pharmaceutically acceptable carrier;
a first group of particles comprising a biocompatible polymer, and a first antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer;
a second group of particles comprising a biocompatible polymer, and a second antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer, the second antigen being different from the first antigen; and
a third group of particles comprising a biocompatible polymer, and a third antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer, the third antigen being different from both the first and second antigen;
wherein each particle in the first group, the second group and the third group is substantially spherical, and each particle has a diameter in a range from 10 microns±20% to 25 microns±20%, wherein the particle diameter is such that only a single particle can be consumed by an antigen presenting cell.
2. The composition of claim 1 , wherein the biocompatible polymer is selected from the group consisting of poly(lactic-co-glycolic acid) (PLGA), polycaprolactone, polyglycolide, polylactic acid, poly-3-hydroxybutyrate.
3. The composition of claim 1 , further comprising:
a plurality of additional groups of particles with a diameter of from 10 microns±20% to 25 microns±20% and a diameter such that only a single particle can be consumed by an antigen presenting cell wherein additional antigens in each additional group are embedded in the polymer and are different from antigen in all other groups and the antigens of each group consisting only of a single species.
4. The composition of claim 3 , wherein all the particles of the composition are 12 microns to 22 microns in diameter±20%.
5. The composition of claim 1 , further comprising monophosphoryl lipid A.
6. The composition as claimed in claim 5 wherein the monophosphoryl lipid A is in the pharmaceutically acceptable carrier.
7. A composition, comprising:
a pharmaceutically acceptable carrier;
a first group of particles comprising a biocompatible polymer, and a first antigen consisting only of a single species embedded in the polymer;
a second group of particles comprising a biocompatible polymer, and a second antigen consisting only of a single species embedded in the polymer, the second antigen being different from the first antigen; and
a third group of particles comprising a biocompatible polymer, and a third antigen consisting only of a single species embedded in the polymer, the third antigen species being different from both the first and second antigen species,
wherein each particle in the first group, second group and third group is substantially spherical, and each particle has a diameter in a range of from 10 microns±20% to 25 microns±20%, wherein the particle diameter is such that only a single particle can be consumed by an antigen presenting cell, and wherein the biocompatible polymer is selected from the group consisting of poly(lactic-co-glycolic acid) (PLGA), polycaprolactone, polyglycolide, polylactic acid, poly-3-hydroxybutyrate,
wherein the first, second and third antigens are each different antigens consisting of eight to twenty amino acids.
8. The composition of claim 7 , further comprising:
a plurality of additional groups of particles with a diameter of from 10 microns±20% to 25 microns±20% and a diameter such that only a single particle can be consumed by an antigen presenting cell wherein additional antigens in each additional group are embedded in the polymer and are different from the antigens in all other groups.
9. The composition of claim 7 , further comprising monophosphoryl lipid A.
10. The composition as claimed in claim 9 wherein the monophosphoryl lipid A is in the pharmaceutically acceptable carrier.
11. The composition of claim 8 , wherein all the particles of the composition are 12 microns to 22 microns in diameter±20%.
12. The composition of claim 8 , wherein all the particles of the composition are 13 microns to 17 microns in diameter±20%.
13. A composition, comprising:
a pharmaceutically acceptable carrier;
a first group of particles comprising a biocompatible polymer, and a first antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer; and
a second group of particles comprising a biocompatible polymer, and a second antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer, the second antigen being different from the first antigen;
a plurality of additional groups of particles with a diameter such that only a single particle can be consumed by an antigen presenting cell wherein additional antigens in each additional group are embedded in the polymer and are different from antigen in all other groups and the antigens of each group consisting only of a single species;
wherein each particle in the first group, the second group, and the additional groups, the diameter being substantially spherical, and has a diameter such that only a single particle can be consumed by an antigen presenting cell, the particle diameter being in a range of from 10 microns±20% to 25 microns±20%;
wherein the biocompatible polymer is selected from the group consisting of poly(lactic-co-glycolic acid) (PLGA), polycaprolactone, polyglycolide, polylactic acid, poly-3-hydroxybutyrate.
14. The composition of claim 13 , further comprising monophosphoryl lipid A.
15. The composition as claimed in claim 14 wherein the monophosphoryl lipid A is in the pharmaceutically acceptable carrier.
16. A vaccine composition, comprising:
a pharmaceutically acceptable carrier;
a first group of particles comprising a biocompatible polymer, and a first antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer;
a second group of particles comprising a biocompatible polymer, and a second antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer, the second antigen being different from the first antigen; and
a third group of particles comprising a biocompatible polymer, and a third antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer, the third antigen being different from both the first and second antigen;
wherein each particle in the first group, the second group and the third group is substantially spherical, and each particle has a diameter in a range from 10 microns±10% to 15 microns±10%, wherein the particle diameter is such that only a single particle can be consumed by an antigen presenting cell.
17. The vaccine composition of claim 16 , wherein the biocompatible polymer is selected from the group consisting of poly(lactic-co-glycolic acid) (PLGA), polycaprolactone, polyglycolide, polylactic acid, poly-3-hydroxybutyrate.
18. The vaccine composition of claim 16 , further comprising:
a plurality of additional groups of particles with a diameter of from 10 microns±10% to 20 microns±10% and a diameter such that only a single particle can be consumed by an antigen presenting cell wherein additional antigens in each additional group are embedded in the polymer and are different from antigen in all other groups and the antigens of each group consisting only of a single species.
19. The vaccine composition of claim 16 , further comprising monophosphoryl lipid A.
20. The vaccine composition as claimed in claim 19 wherein the monophosphoryl lipid A is in the pharmaceutically acceptable carrier.